Silk Road Medical stock tanks after CMS decision on carotid artery stenting prompts analyst downgrade
Shares of Silk Road Medical Inc. (SILK) tanked 21.9% toward a more-than three-year low in premarket Tuesday, after an unfavorable government decision regarding Medicare coverage of carotid artery stenting. The Centers for Medicare & Medicaid Services (CMS) proposed that coverage of percutaneous transluminal angioplasty (PTA) of carotid arteries concurrent with stenting (CAS) is "reasonable and necessary" with devices approved or cleared with the Food and Drug Administration. J.P. Morgan analyst Robert Marcus followed by downgrading Silk Road to neutral, after being at overweight for at least three years, as the CMS decision means CAS is now on par with Silk Road's treatment of carotid artery disease, called TransCarotid Artery Revascularization (TCAR). "While this event has been on most investors' radars for some time, and many were expecting exactly this outcome, it is nevertheless places a difficult overhang on the stock, one that will take time to either confirm or disprove," Marcus wrote in a note to clients. The stock has plunged 51.8% year to date, while the S&P 500 has advanced 16.6%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-12-23 0940ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track